Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 109 articles: HTML format Text format

Single Articles

February 2020
1. SZTUPINSZKI Z, Diossy M, Krzystanek M, Borcsok J, et al
   Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
   Clin Cancer Res. 2020 Feb 18. pii: 1078-0432.CCR-19-2135.
   PubMed     Text format     Abstract available
   
   
   January 2020
2. FAISAL FA, Murali S, Kaur H, Vidotto T, et al
   CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer.
   Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-1669.
   PubMed     Text format     Abstract available
   
   
   
3. CORN PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, et al
   A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer.
   Clin Cancer Res. 2020 Jan 15. pii: 1078-0432.CCR-19-2389.
   PubMed     Text format     Abstract available
   
   
   
4. AGARWAL N, Nussenzveig RH, Hahn AW, Hoffman JM, et al
   Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.
   Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2591.
   PubMed     Text format     Abstract available
   
   
   
5. LI Y, Yang R, Henzler CM, Ho Y, et al
   Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.
   Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-19-3023.
   PubMed     Text format     Abstract available
   
   
   
6. NOURI M, Massah S, Caradec J, Lubik AA, et al
   Transient Sox9 Expression Facilitates Progression to Castrate Resistant Prostate Cancer.
   Clin Cancer Res. 2020 Jan 9. pii: 1078-0432.CCR-19-0098.
   PubMed     Text format     Abstract available
   
   
   
7. SCHWEIZER MT, Yu EY
   "Matching" the "mismatch" repair deficient prostate cancer with immunotherapy.
   Clin Cancer Res. 2020 Jan 3. pii: 1078-0432.CCR-19-3780.
   PubMed     Text format     Abstract available
   
   
   
8. SHANKAR S, Ganapathy S, Srivastava RK
   Editor's Note: Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis.
   Clin Cancer Res. 2020;26:312.
   PubMed     Text format    
   
   
   December 2019
9. HAMMER S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, et al
   Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer.
   Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-2268.
   PubMed     Text format     Abstract available
   
   
   
10. CORELLA AN, Cabiliza Ordonio MVA, Coleman I, Lucas JM, et al
    Identification of Therapeutic Vulnerabilities in Small Cell Neuroendocrine Prostate Cancer.
    Clin Cancer Res. 2019 Dec 5. pii: 1078-0432.CCR-19-0775.
    PubMed     Text format     Abstract available
    
    
    
11. CHAKRABORTY G, Armenia J, Mazzu YZ, Nandakumar S, et al
    Significance of BRCA2 and RB1 co-loss in aggressive prostate cancer progression.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-1570.
    PubMed     Text format     Abstract available
    
    
    
12. CHEN K, Cao Q, Song Z, Ruan H, et al
    Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-0396.
    PubMed     Text format     Abstract available
    
    
    November 2019
13. ALLOTT EH, Ebot EM, Stopsack KH, Gonzalez-Feliciano AG, et al
    Statin use is associated with lower risk of PTEN-null and lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2853.
    PubMed     Text format     Abstract available
    
    
    
14. RITCH E, Fu SYF, Herberts C, Wang G, et al
    Identification of hypermutation and defective mismatch repair in ctDNA from metastatic prostate cancer.
    Clin Cancer Res. 2019 Nov 19. pii: 1078-0432.CCR-19-1623.
    PubMed     Text format     Abstract available
    
    
    
15. GLUMAC PM, Gallant JP, Shapovalova M, Li Y, et al
    Exploitation of CD133 for the targeted imaging of lethal prostate cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-19-1659.
    PubMed     Text format     Abstract available
    
    
    October 2019
16. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Clinical Significance of AR-V567es in Prostate Cancer-Response.
    Clin Cancer Res. 2019;25:6010-6011.
    PubMed     Text format    
    
    
    
17. UO T, Plymate SR
    Clinical Significance of AR-V567es in Prostate Cancer-Letter.
    Clin Cancer Res. 2019;25:6009.
    PubMed     Text format    
    
    
    September 2019
18. SPRATT DE, Alshalalfa M, Fishbane N, Weiner AB, et al
    Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-1587.
    PubMed     Text format     Abstract available
    
    
    
19. FENDLER WP, Weber M, Iravani A, Hofman MS, et al
    Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 11. pii: 1078-0432.CCR-19-1050.
    PubMed     Text format     Abstract available
    
    
    
20. PONNUSAMY S, He Y, Hwang DJ, Thiyagarajan T, et al
    Orally-Bioavailable Androgen Receptor Degrader, A Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Sep 3. pii: 1078-0432.CCR-19-1458.
    PubMed     Text format     Abstract available
    
    
    August 2019
21. LIU B, Li L, Yang G, Geng C, et al
    PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0317.
    PubMed     Text format     Abstract available
    
    
    
22. BHAGIRATH D, Yang TL, Tabatabai ZL, Majid S, et al
    BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2.
    Clin Cancer Res. 2019 Aug 1. pii: 1078-0432.CCR-19-0498.
    PubMed     Text format     Abstract available
    
    
    July 2019
23. BELTRAN H, Hruszkewycz A, Scher HI, Hildesheim J, et al
    The role of lineage plasticity in prostate cancer therapy resistance.
    Clin Cancer Res. 2019 Jul 30. pii: 1078-0432.CCR-19-1423.
    PubMed     Text format     Abstract available
    
    
    
24. KOTHARI V, Goodwin JF, Zhao SG, Drake JM, et al
    DNA-dependent protein kinase drives prostate cancer progression through transcriptional regulation of the Wnt signaling pathway.
    Clin Cancer Res. 2019 Jul 2. pii: 1078-0432.CCR-18-2387.
    PubMed     Text format     Abstract available
    
    
    May 2019
25. SLOVIN SF, Hussain S, Saad F, Garcia JA, et al
    Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3212.
    PubMed     Text format     Abstract available
    
    
    
26. KULP SK, Chen CS, Wang DS, Chen CY, et al
    Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
    Clin Cancer Res. 2019;25:2940.
    PubMed     Text format    
    
    
    April 2019
27. MAZZU YZ, Armenia J, Chakraborty G, Yoshikawa Y, et al
    A novel mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2 (RRM2).
    Clin Cancer Res. 2019 Apr 17. pii: 1078-0432.CCR-18-4046.
    PubMed     Text format     Abstract available
    
    
    
28. WEST JB, Dinh MN, Brown JS, Zhang J, et al
    Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-19-0006.
    PubMed     Text format     Abstract available
    
    
    
29. BERNEMANN C, Humberg V, Thielen B, Steinestel J, et al
    Comparative analysis of AR variant AR-V567es mRNA detection systems reveals eminent variability and questions the role as a clinical biomarker in prostate cancer.
    Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-4276.
    PubMed     Text format     Abstract available
    
    
    
30. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Correction: Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2019;25:2672.
    PubMed     Text format    
    
    
    
31. LIU YN, Niu S, Chen WY, Zhang Q, et al
    Leukemia inhibitory factor promotes castration-resistant prostate cancer and neuroendocrine differentiation by activated ZBTB46.
    Clin Cancer Res. 2019 Apr 8. pii: 1078-0432.CCR-18-3239.
    PubMed     Text format     Abstract available
    
    
    March 2019
32. KREGEL S, Malik R, Asangani IA, Wilder-Romans K, et al
    Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2019 Mar 27. pii: 1078-0432.CCR-18-3776.
    PubMed     Text format     Abstract available
    
    
    
33. REBELLO RJ, Oing C, Gillessen S, Bristow RG, et al
    TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?
    Clin Cancer Res. 2019;25:1699-1701.
    PubMed     Text format     Abstract available
    
    
    
34. DEHM SM, Montgomery B, Plymate SR
    AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?
    Clin Cancer Res. 2019;25:1696-1698.
    PubMed     Text format     Abstract available
    
    
    February 2019
35. BJARTELL A
    New hope in prostate cancer precision medicine? miRNA replacement and epigenetics.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-19-0061.
    PubMed     Text format     Abstract available
    
    
    
36. URABE F, Matsuzaki J, Yamamoto Y, Kimura T, et al
    Large-scale circulating microRNA profiling for the liquid biopsy of prostate cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-2849.
    PubMed     Text format     Abstract available
    
    
    January 2019
37. MOHAMMADPOUR H, Bucsek MJ, Hylander BL, Repasky EA, et al
    Depression stresses the immune response and promotes prostate cancer growth.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-3980.
    PubMed     Text format     Abstract available
    
    
    December 2018
38. BHATIA V, Yadav A, Tiwari R, Nigam S, et al
    Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-3230.
    PubMed     Text format     Abstract available
    
    
    
39. MOSTAGHEL EA
    Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer.
    Clin Cancer Res. 2018 Dec 10. pii: 1078-0432.CCR-18-3410.
    PubMed     Text format     Abstract available
    
    
    November 2018
40. CHENG Y, Tang X, Li Y, Zhao D, et al
    Depression induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells.
    Clin Cancer Res. 2018 Nov 30. pii: 1078-0432.CCR-18-2912.
    PubMed     Text format     Abstract available
    
    
    October 2018
41. VAISHAMPAYAN U, Podgorski I, Heilbrun LK, Lawhorn-Crews JM, et al
    Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1473.
    PubMed     Text format     Abstract available
    
    
    
42. GARRIDO MF, Martin NJ, Bertrand M, Gaudin C, et al
    Regulation of eIF4F translation initiation complex by the peptidyl prolyl isomerase FKBP7 in taxane-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-0704.
    PubMed     Text format     Abstract available
    
    
    
43. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1807.
    PubMed     Text format     Abstract available
    
    
    
44. TAGAWA ST, Antonarakis ES, Gjyrezi A, Galletti G, et al
    Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY.
    Clin Cancer Res. 2018 Oct 9. pii: 1078-0432.CCR-18-0320.
    PubMed     Text format     Abstract available
    
    
    
45. FLORES-MORALES A, Bergmann TB, Lavallee C, Batth TS, et al
    Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Oct 1. pii: 1078-0432.CCR-18-0729.
    PubMed     Text format     Abstract available
    
    
    September 2018
46. NAVA RODRIGUES D, Casiraghi N, Romanel A, Crespo M, et al
    RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 26. pii: 1078-0432.CCR-18-2068.
    PubMed     Text format     Abstract available
    
    
    
47. BELTRAN H, Oromendia C, Danila DC, Montgomery B, et al
    A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.
    Clin Cancer Res. 2018 Sep 19. pii: 1078-0432.CCR-18-1912.
    PubMed     Text format     Abstract available
    
    
    
48. GAO X, Dai C, Huang S, Tang J, et al
    Functional silencing of HSD17B2 in prostate cancer promotes disease progression.
    Clin Cancer Res. 2018 Sep 18. pii: 1078-0432.CCR-18-2392.
    PubMed     Text format     Abstract available
    
    
    
49. FERRARI AC, Alumkal JJ, Stein MN, Taplin ME, et al
    Epigenetic Therapy with Panobinostat Combined with Bicalutamide Re-challenge in Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1589.
    PubMed     Text format     Abstract available
    
    
    
50. DE LAERE B, Oeyen S, Mayrhofer M, Whitington T, et al
    TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2018 Sep 12. pii: 1078-0432.CCR-18-1943.
    PubMed     Text format     Abstract available
    
    
    
51. ZHANG T, George DJ, Armstrong AJ
    Precision medicine approaches when prostate cancer Akts up.
    Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-2491.
    PubMed     Text format     Abstract available
    
    
    
52. KULARATNE SA, Thomas M, Myers CH, Gagare P, et al
    Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery for Prostate Cancer.
    Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-0803.
    PubMed     Text format     Abstract available
    
    
    
53. ROSATI R, Polin LA, Ducker C, Li J, et al
    Strategy for Tumor Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-0982.
    PubMed     Text format     Abstract available
    
    
    
54. SIPEKY C, Gao P, Zhang Q, Wang L, et al
    Synergistic interaction of HOXB13 and CIP2A predispose to aggressive prostate cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-0444.
    PubMed     Text format     Abstract available
    
    
    
55. MOSTAGHEL EA, Zhang A, Hernandez S, Marck B, et al
    Contribution of Adrenal Glands to Intra-tumor Androgens and Growth of Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 4. pii: 1078-0432.CCR-18-1431.
    PubMed     Text format     Abstract available
    
    
    August 2018
56. GRUBMULLER B, Baltzer PA, Hartenbach S, D'Andrea D, et al
    PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0768.
    PubMed     Text format     Abstract available
    
    
    
57. LAMBROS MB, Seed G, Sumanasuriya S, Gil V, et al
    Single Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0862.
    PubMed     Text format     Abstract available
    
    
    
58. GANAIE A, Beigh FH, Astone M, Ferrari MG, et al
    BMI1 drives metastasis of prostate cancer in Caucasian and African-American men and is a potential therapeutic target: hypothesis tested in race-specific models.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1394.
    PubMed     Text format     Abstract available
    
    
    
59. BARBER LE, Gerke T, Markt SC, Peisch SF, et al
    Family history of breast or prostate cancer and prostate cancer risk.
    Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0370.
    PubMed     Text format     Abstract available
    
    
    
60. BOYSEN G, Nava Rodrigues D, Rescigno P, Seed G, et al
    SPOP mutated/ CHD1 deleted lethal prostate cancer and abiraterone sensitivity.
    Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-0937.
    PubMed     Text format     Abstract available
    
    
    July 2018
61. IGLESIAS-GATO D, Thysell E, Tyanova S, Crnalic S, et al
    The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications.
    Clin Cancer Res. 2018 Jul 24. pii: 1078-0432.CCR-18-1229.
    PubMed     Text format     Abstract available
    
    
    
62. DE BONO JS, De Giorgi U, Nava Rodrigues D, Massard C, et al
    Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss.
    Clin Cancer Res. 2018 Jul 23. pii: 1078-0432.CCR-18-0981.
    PubMed     Text format     Abstract available
    
    
    
63. TOREN P, Hoffman A, Ding K, Joncas FH, et al
    Serum sex steroids as prognostic biomarkers in patients receiving androgen deprivation therapy for recurrent prostate cancer: a post-hoc analysis of the PR.7 trial.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-1187.
    PubMed     Text format     Abstract available
    
    
    
64. ARAI S, Jonas O, Whitman M, Corey E, et al
    Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0549.
    PubMed     Text format     Abstract available
    
    
    
65. LIU Q, Tong D, Liu G, Gao J, et al
    Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0420.
    PubMed     Text format     Abstract available
    
    
    
66. GUPTA S, Nordquist LT, Fleming MT, Berry WR, et al
    Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-0564.
    PubMed     Text format     Abstract available
    
    
    
67. TANG W, Wallace TA, Yi M, Magi-Galluzzi C, et al
    IFNL4-DeltaG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer.
    Clin Cancer Res. 2018 Jul 16. pii: 1078-0432.CCR-18-1060.
    PubMed     Text format     Abstract available
    
    
    June 2018
68. ANTONARAKIS ES, Small EJ, Petrylak D, Quinn DI, et al
    Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival.
    Clin Cancer Res. 2018 Jun 1. pii: 1078-0432.CCR-18-0638.
    PubMed     Text format     Abstract available
    
    
    May 2018
69. BLEE AM, He Y, Yang Y, Ye Z, et al
    TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in PTEN and TP53-mutated prostate cancer.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-18-0653.
    PubMed     Text format     Abstract available
    
    
    
70. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
    High-fat Diet-induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling.
    Clin Cancer Res. 2018 May 18. pii: 1078-0432.CCR-18-0106.
    PubMed     Text format     Abstract available
    
    
    
71. ALSHALALFA M, Karnes RJ, Sharma V, Choeurng V, et al
    Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy.
    Clin Cancer Res. 2018 May 14. pii: 1078-0432.CCR-17-2745.
    PubMed     Text format     Abstract available
    
    
    
72. 
    Correction: Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2018;24:2234.
    PubMed     Text format    
    
    
    
73. BHANVADIA RR, VanOpstall C, Brechka H, Barashi NS, et al
    MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.
    Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3673.
    PubMed     Text format     Abstract available
    
    
    April 2018
74. HUANG H, Wang C, Liu F, Li HZ, et al
    Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-18-0461.
    PubMed     Text format     Abstract available
    
    
    
75. SHIH TC, Liu R, Wu CT, Li X, et al
    Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion.
    Clin Cancer Res. 2018 Apr 17. pii: 1078-0432.CCR-18-0157.
    PubMed     Text format     Abstract available
    
    
    
76. GORDEVICIUS J, Krisciunas A, Groot DE, Yip SM, et al
    Cell-free DNA modification dynamics in abiraterone acetate-treated prostate cancer patients.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0101.
    PubMed     Text format     Abstract available
    
    
    March 2018
77. SCROGGINS B, Matsuo M, White A, Saito K, et al
    Hyperpolarized [1-(13)C]-pyruvate magnetic resonance spectroscopic imaging of prostate cancer in vivo predicts efficacy of targeting the Warburg effect.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1957.
    PubMed     Text format     Abstract available
    
    
    
78. WELTI J, Sharp A, Yuan W, Dolling DI, et al
    Targeting bromodomain and extra-terminal (BET) family proteins in castration resistant prostate cancer (CRPC).
    Clin Cancer Res. 2018 Mar 19. pii: 1078-0432.CCR-17-3571.
    PubMed     Text format     Abstract available
    
    
    February 2018
79. MARANTO C, Udhane V, Hoang DT, Gu L, et al
    STAT5A/B BLOCKADE SENSITIZES PROSTATE CANCER TO RADIATION THROUGH INHIBITION OF RAD51 AND DNA REPAIR.
    Clin Cancer Res. 2018 Feb 26. pii: 1078-0432.CCR-17-2768.
    PubMed     Text format     Abstract available
    
    
    
80. HECK MM, Retz M, Bandur M, Souchay M, et al
    Molecular lymph node status for prognostic stratification of prostate cancer patients undergoing radical prostatectomy with extended pelvic lymph node dissection.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3771.
    PubMed     Text format     Abstract available
    
    
    
81. KIM K, Watson PA, Lebdai S, Jebiwott S, et al
    Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-17-3474.
    PubMed     Text format     Abstract available
    
    
    November 2017
82. WANG C, Peng G, Huang H, Liu F, et al
    Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Clin Cancer Res. 2017 Nov 30. pii: 1078-0432.CCR-17-2446.
    PubMed     Text format     Abstract available
    
    
    
83. YANG Y, Bai Y, He Y, Zhao Y, et al
    PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer.
    Clin Cancer Res. 2017 Nov 22. pii: clincanres.2006.2017.
    PubMed     Text format     Abstract available
    
    
    
84. PUHR M, Hoefer J, Eigentler A, Ploner C, et al
    The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy.
    Clin Cancer Res. 2017 Nov 20. pii: clincanres.0989.2017.
    PubMed     Text format     Abstract available
    
    
    
85. BELDERBOS BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, et al
    Influence of Enzalutamide on Cabazitaxel Pharmacokinetics; a Drug-Drug Interaction Study in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients.
    Clin Cancer Res. 2017 Nov 17. pii: clincanres.2336.2017.
    PubMed     Text format     Abstract available
    
    
    
86. ZHANG W, Liu B, Wu W, Li L, et al
    Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.1872.2017.
    PubMed     Text format     Abstract available
    
    
    
87. PALLER CJ, Zhou XC, Heath EI, Taplin ME, et al
    Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1100.2017.
    PubMed     Text format     Abstract available
    
    
    September 2017
88. KALINA JL, Neilson DS, Lin YY, Hamilton PT, et al
    Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T cell Epitopes & Immune Signatures in a Subset of Prostate Cancer.
    Clin Cancer Res. 2017 Sep 27. pii: clincanres.0618.2017.
    PubMed     Text format     Abstract available
    
    
    
89. LABBE DP, Sweeney CJ, Brown M, Galbo P, et al
    TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0413.2017.
    PubMed     Text format     Abstract available
    
    
    
90. KETOLA K, Munuganti RS, Davies A, Nip KM, et al
    Targeting Prostate Cancer Subtype 1 by Forkhead box M1 Pathway Inhibition.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.0901.2017.
    PubMed     Text format     Abstract available
    
    
    
91. CALAGUA C, Russo J, Sun Y, Schaefer R, et al
    Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Clin Cancer Res. 2017 Sep 11. pii: clincanres.0807.2017.
    PubMed     Text format     Abstract available
    
    
    August 2017
92. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Text format     Abstract available
    
    
    
93. GUEDES L, Antonarakis ES, Schweizer MT, Mirkheshti N, et al
    MSH2 Loss in Primary Prostate Cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0955.2017.
    PubMed     Text format     Abstract available
    
    
    July 2017
94. GAO WQ, Guo Y, Zhang K, Cheng C, et al
    Numb-/low enriches a castration resistant prostate cancer cell subpopulation associated with enhanced Notch and Hedgehog signaling.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0913.2017.
    PubMed     Text format     Abstract available
    
    
    
95. SEED G, Yuan W, Mateo J, Carreira S, et al
    Gene Copy Number Estimation From Targeted Next Generation Sequencing Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.0972.2017.
    PubMed     Text format     Abstract available
    
    
    
96. 
    Retraction: GRM1 is An Androgen-Regulated Gene and its Expression Correlates with Prostate Cancer Progression in Pre-Clinical Models.
    Clin Cancer Res. 2017;23:3973.
    PubMed     Text format    
    
    
    
97. 
    Correction: A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2017;23:3970.
    PubMed     Text format    
    
    
    June 2017
98. BILUSIC M, Madan RA, Gulley JL
    Immunotherapy of Prostate Cancer: Facts and Hopes.
    Clin Cancer Res. 2017 Jun 29. pii: clincanres.0019.2017.
    PubMed     Text format     Abstract available
    
    
    
99. XU L, Mao X, Guo T, Chan PY, et al
    The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis.
    Clin Cancer Res. 2017 Jun 14. pii: clincanres.3081.2016.
    PubMed     Text format     Abstract available
    
    
    May 2017
100. BAN K, Feng S, Shao L, Ittmann M, et al
     RET signaling in prostate cancer.
     Clin Cancer Res. 2017 May 10. pii: clincanres.0528.2017.
     PubMed     Text format     Abstract available
     
     
     
101. KOHLI M, Ho Y, Hillman DW, Van Etten JL, et al
     Androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
     Clin Cancer Res. 2017 May 4. pii: clincanres.0017.2017.
     PubMed     Text format     Abstract available
     
     
     
102. MONTGOMERY B, Tretiakova MS, Joshua AM, Gleave ME, et al
     Neoadjuvant Enzalutamide Prior to Prostatectomy.
     Clin Cancer Res. 2017;23:2169-2176.
     PubMed     Text format     Abstract available
     
     
     April 2017
103. GUEDES L, Almutairi F, Haffner MC, Rajoria G, et al
     Analytic, Pre-analytic and Clinical Validation of p53 Immunohistochemistry for Detection of TP53 Missense Mutation in Prostate Cancer.
     Clin Cancer Res. 2017 Apr 26. pii: clincanres.0257.2017.
     PubMed     Text format     Abstract available
     
     
     
104. MOSTAGHEL EA, Cho E, Zhang A, Alyamani M, et al
     Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.
     Clin Cancer Res. 2017 Apr 7. pii: clincanres.2245.2016.
     PubMed     Text format     Abstract available
     
     
     
105. NIEUWEBOER AJ, de Graan AM, Hamberg P, Bins S, et al
     Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
     Clin Cancer Res. 2017;23:1679-1683.
     PubMed     Text format     Abstract available
     
     
     
106. NESBITT H, Byrne NM, Williams SN, Ming L, et al
     Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
     Clin Cancer Res. 2017;23:1797-1808.
     PubMed     Text format     Abstract available
     
     
     March 2017
107. SUOMINEN MI, Fagerlund KM, Rissanen JP, Konkol YM, et al
     Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models.
     Clin Cancer Res. 2017 Mar 31. pii: clincanres.2955.2016.
     PubMed     Text format     Abstract available
     
     
     January 2017
108. SINNOTT JA, Peisch SF, Tyekucheva S, Gerke T, et al
     Prognostic Utility of a New mRNA Expression Signature of Gleason Score.
     Clin Cancer Res. 2017;23:81-87.
     PubMed     Text format     Abstract available
     
     
     May 2016
109. CHUA ML, Bristow RG
     Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or <I>Frenemy</I>?
     Clin Cancer Res. 2016 May 10. pii: clincanres.0381.2016.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: